The most interesting part of the Seeking Alpha article was the mention of Merck purchasing Cubist Pharmaceutical. After doing a little research, Cubist was bought out for $9.5 bil, and at the time had just over $1bil in annual revenue.
Using this same valuation applied to 2022 PRTK sales, the price per share would be approximately $40 per share.
M
New Seeking Alpha article, really interesting! "Paratek Pharmaceuticals: A Deeply Undervalued Antibiotic Company"
B
Zai Labs which has a $6bil market cap, is up 4% on the news that Nuzyra has been approved for its phase 3 study. This equates to $240mil increase in market cap. In comparison, PRTK has a market cap of $240mil, owns the rights for Nuzyra everywhere else in the world. Already has $150mil in sales, and will get to $200+mil by next year. Yet it's not even worth the one day move Zai labs made on phase 3 approval of the drug PRTK owns and will get royalties on.
I can't even make this stuff up, its comedy gold.
V
Interesting stock performance today... PRTK considerably in the green area, while most biotechs unfortunately are bleeding (again).
Paratek doing everything right. Can't wait to see China's additional revenue next year.
Conference call said they have hundreds of sales reps educated & ready to sell Nuzyra
V
Paratek has a forward P/E of 15 as Nuzyra sales are growing strong and further BARDA payments are expected, but even so the stock was beaten down to a new 52 week low. Unbelievable!
T
Question? Is anybody aware if PRTK has ever investigated the use of Nuzyra for Lyme's disease. Currently the automatic remedy for Lyme's is doxycycline. This is a rapidly growing market in the US.
B
Even Loh, on Jeffries London Healthcare conference, mentioned the NTM market in Japan is the same size as the US....$1bil. This is the same for South Korea. Needless to say NTM is a huge market for this drug, which in the US, Japan, and South Korea is upwards of $3bil annually. Can someone please explain to me why this isn't valued much higher than it currently is??? This stock is deep value, the market doesn't see it yet because it is distracted by the glittering gold objects like high flying Tech growth companies. When the rug is pulled from under the markets delusional valuations, this stock will be here to stay with solid valuations for years to come. Don't get weak hands and let this go.
C
Are they building their own factory to produce nuyzra or commissioned it out to another company?
Y
Paratek Pharmaceuticals is down 5.81% to 3.73
B
I'm beginning to think management and big investors are actively crushing this stock so they can come crawling to the government with their head tucked between their legs. There's no way in a normal world, this stock would be worth so little. Some other antibiotic companies with less sales, and earlier staged drug development are doubkt the value (look at SMMT for example). When the stock was at its highs, BARDA delayed a payment, clearly they want the stock to be at lows until the big contract or even PASTEUR Act/DISARM act are passed. Until then I will wait because there is so much value in this stock it's sickening.
Y
Paratek Pharmaceuticals reached a 52 Week low at 4.50
Y
Paratek Pharmaceuticals is up 6.07% to 4.54
P
Stated in Conference Call they feel very confident about getting $6 Million royalty payment with China FDA equivalent approval, this year.
Zai labs has invested heavily in Nuzyra launch & hundreds of infectious disease sales reps are up to speed & ready to sell into China's Tier 1 cities first.
They have hyped China up for years & cool to get some details, this close to GO TIME.
Stock is screaming buy @ this price ($250 million market cap)
Y
Paratek Pharmaceuticals is down 5.49% to 3.79
B
Great quarter, showing strong growth at 30% QoQ. Cash flow break even still anticipated by 2023. Which means at least $200mil in annual sales by then (without BARDA). My question is, what catalyst does the market need to start a strong movement in Share price. We need Evan Loh and other management to put their money where their mouth is and buy some shares.
V
Strong Q3 earnings and outlook!
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business alone, a 30% Increase over Prior Quarter
-- BARDA Contract Expanded to Include sNDA Anthrax Post-Exposure Prophylaxis Development Program; Contract now Valued at up to $304 Million
-- First Patient Enrolled in Phase 2b Study in Non-Tuberculous Mycobacterium (NTM) Abscessus
Using this same valuation applied to 2022 PRTK sales, the price per share would be approximately $40 per share.
I can't even make this stuff up, its comedy gold.
Paratek doing everything right. Can't wait to see China's additional revenue next year.
Conference call said they have hundreds of sales reps educated & ready to sell Nuzyra
Zai labs has invested heavily in Nuzyra launch & hundreds of infectious disease sales reps are up to speed & ready to sell into China's Tier 1 cities first.
They have hyped China up for years & cool to get some details, this close to GO TIME.
Stock is screaming buy @ this price ($250 million market cap)
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business alone, a 30% Increase over Prior Quarter
-- BARDA Contract Expanded to Include sNDA Anthrax Post-Exposure Prophylaxis Development Program; Contract now Valued at up to $304 Million
-- First Patient Enrolled in Phase 2b Study in Non-Tuberculous Mycobacterium (NTM) Abscessus